Louise Bannon: Thomas Reiser to Step Down as ISTH Executive Director
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, reposted from International Society on Thrombosis and Haemostasis on LinkedIn:
”Today, the International Society on Thrombosis and Haemostasis (ISTH) shared that Thomas Reiser will step down as Executive Director at the end of 2025.
Tom has led the Society with dedication and strategic vision for more than 14 years, and we are deeply grateful for his tremendous service, mentorship and commitment to strengthening our global community. We look forward to continuing to work closely with him through the remainder of the year as we prepare for this transition.
I am honored to step into the role of Interim Executive Director on January 1 and it is a privilege to serve our members, partners and the global thrombosis and hemostasis community during this important chapter for the Society.
Our mission remains clear and our momentum strong. In the months ahead, I look forward to partnering with our exceptional staff, volunteer leaders and valued stakeholders to continue advancing science, education and advocacy for the benefit of patients worldwide.
To all who support our work, especially our talented staff, thank you. Your dedication and heart power everything we do. I feel fortunate to work alongside you and look forward to continuing our important work together in the months ahead.”
Quoting International Society on Thrombosis and Haemostasis‘s post:
”The ISTH announces that Thomas Reiser will step down from his position as Executive Director, following a commendable 14-year period of leadership at the Society. As part of a carefully planned transition, the ISTH Council appoints Louise St. Germain, ISTH Director of Membership, Marketing and External Relations, to the role of Interim Executive Director effective on January 1, 2026. As the search for a permanent Executive Director commences, the ISTH looks forward to the opportunities ahead and to the Society continuing to evolve, innovate and strengthen its impact for the benefit of the global thrombosis and hemostasis community.
Read more.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT